Parnell Pharmaceuticals Holdings Ltd Announces Business Results for the Nine Months Ended September 30, 2017

Jan 15, 2018

Parnell Pharmaceuticals Holdings Ltd. (OTC PINK: PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced business results for the period ended September 30, 2017, including ongoing revenue growth of 4% to $14.4 million, a $12.6 million improvement in profitability to an EBITDAOI loss of $0.6 million year to date and advances in partnering negotiations and contract manufacturing agreements. Brad McCarthy, CEO and Executive Director of the Board, said, “Parnell furthered its sales growth in the September quarter whilst maintaining a strong emphasis on cost control to progress towards our communicated goal of becoming EBITDA (being Earnings Before Interest, Tax, Depreciation, Amortization) break-even in 2017. “Through 30 September proprietary in-Market product sales in our key US Production business remained on track with 2017 guidance delivering 22% growth over the same period in 2016, although changes in distributor purchasing patterns saw our ex-Parnell sales grow 2% for the period. This strong in-Market growth continues despite not having a full complement of territory... ...

Read More

Parnell Appoints Tony G Hartnell AM to Board of Directors

Jan 8, 2018

Parnell Pharmaceuticals Holdings Ltd (OTC: PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced the appointment of Anthony G Hartnell AM to its Board of Directors. “We are indeed fortunate to be able to welcome Tony Hartnell AM to our Board. His acceptance of a directorship secures us an exceptional Independent Director with impeccable credentials in business success, enterprise financing and good governance, and unique expertise in corporate law and regulation,” said Dr. Alan Bell, Chairman of Parnell. “Mr. Hartnell brings a wealth of knowledge and experience to our Board, having chaired five publicly listed companies including BT Global Asset Management Ltd, Television & Media Services Ltd and Chiquita Brands South Pacific Ltd. “His distinguished career also included his service as the Inaugural Chairman of the Australian Securities Commission and Chairman of the National Companies and Securities Commission. Under the national Honours system, Mr. Hartnell was awarded Member in the Order of Australia (AM), and subsequently the Centenary Medal, in recognition... ...

Read More

At the Frontiers of Animal Health: A European Perspective

Dec 21, 2017

Constantly presenting new possibilities for the prevention and treatment of disease. Directive 2001/82/ EC, which both sets out standards for veterinary medicinal products and outlines the authorisation procedures, focuses on the established pharmaceutical and immunological product types, and has no scope to provide a framework for innovative products that fall outside these categories. Anja Holm, independent consultant at Central VetPharma Consultancy, and Pascale Canning at Cyton Biosciences discuss how this can often frustrate and confuse companies wishing to market a product, and may be a block to useful products becoming available to veterinarians, farmers, and pet owners. ...

Read More

Towards an Enabling Regulatory Environment for Livestock Health

Dec 21, 2017

Animal health management has important implications for poverty reduction and economic growth. Edna Kallon, K. Aleks Schaefer and Felix Frewer at Worldbank discuss the importance of good regulations to encourage the registration of quality assured products, and provide a snapshot of initial results of data collection efforts for the regulation of VMPs. ...

Read More

Tri-Solfen registered in New Zealand for sheep and cattle husbandry procedures

Nov 16, 2017

Medical Ethics Pty Ltd (“Medical Ethics” or “the Group”), a commercial and development company focused on pain mitigation in wounds for humans and animals, announces that its wholly owned subsidiary, Animal Ethics Pty Ltd (Animal Ethics), has successfully registered Tri-Solfen in New Zealand for sheep and cattle husbandry procedures. Tri-Solfen is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improve wound healing. Tri-Solfen was registered through the Ministry for Primary Industries, which leads and facilitates the management of animal welfare policy and practice in New Zealand.   Over one billion livestock animals globally undergo highly invasive painful husbandry procedures annually. Tri-Solfen is already registered in Australia separately for sheep and cattle husbandry procedures, where it is marketed and distributed by Bayer Animal Health, a global leader in animal health. To date, Tri-Solfen has been used to successfully treat over 80 million animals undergoing routine surgeries in the Australian livestock industries.   Animal Ethics accelerated the... ...

Read More